Walter M. Stadler to Neovascularization, Pathologic
This is a "connection" page, showing publications Walter M. Stadler has written about Neovascularization, Pathologic.
Connection Strength
1.431
-
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
Score: 0.333
-
Angiogenesis inhibition in non-clear cell renal cancer. Clin Adv Hematol Oncol. 2008 Jul; 6(7):507-9.
Score: 0.263
-
Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development. Clin Cancer Res. 2007 Mar 15; 13(6):1630-3.
Score: 0.240
-
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
Score: 0.212
-
Angiogenesis inhibitors. Curr Oncol Rep. 2000 Jan; 2(1):11-6.
Score: 0.146
-
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. Technol Cancer Res Treat. 2013 Feb; 12(1):71-8.
Score: 0.087
-
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):678-89.
Score: 0.052
-
Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S41-7.
Score: 0.046
-
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496.
Score: 0.040
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
Score: 0.012